Efficacy and Safety of Pravastatin in Placental-Related Disorders: Systematic Review And Meta-Analysis Of Randomized Controlled Trials
english
Keywords:
Плацентарные расстройства; Правастатин; Профилактика;Abstract
Placental-related disorders impact over 33% of pregnancies. Several of these syndromes lead to higher rates of maternal and fetal death and morbidity and can have long-term health consequences. Several RCTs have found that pravastatin is associated with a significant reduction in the incidence of preterm preeclampsia and preterm birth. However, alternatives require substantial evidence. On the methods, two writers assessed the risk of bias. The Cochran test was used to assess heterogeneity among studies. The Mantel-Haenszel technique was used to obtain the results. The study's results were described using forest plots. The study used six randomized controlled trials. Findings showed a reduced risk of preeclampsia, preterm birth, and NICU admission in pregnant women taking pravastatin. There was no significant reduction in the risk of neonatal respiratory distress, congenital disorders, and adverse events of headache, heartburn, and musculoskeletal pain. Our conclusion, this study suggests that pravastatin use may have beneficial effects in reducing the risk of placental-related disorders in patients.
References
ACOG Practice Bulletins. Clinical management guidelines for obstetrician- gynecologists. Obstetrics Gynecol. 2020; 133 (76), 168-186.
Karrar SA, Martingano DJ, Hong PL. Preeclampsia. [Updated 2024 Feb 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570611/
Perkumpulan Obstetri dan Ginekologi Indonesia Himpunan Kedokteran Feto Maternal. Pedoman Nasional Pelayanan Kedokteran: Diagnosis dan Tatalaksana Preeklampsia. 2016. Available from: https://www.pogi.or.id/wp-content/uploads/download-manager-files/PNPK%20PreEklampsia%202016.pdf
Marrs CC, Costantine MM. Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women? Clin Obstet Gynecol. 2017;60(1):161-168.
https://doi.org/10.1097/GRF.0000000000000248
Fox R, Kitt J, Leeson P, et al. Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring. J Clin Med. 2019 Oct 4;8 (10):1625.
https://doi.org/10.3390/jcm8101625
Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: Meta-analysis of randomised controlled trials. BMJ. 2009; 339 (7711): b2376.
https://doi.org/10.1136/bmj.b2376
Costantine MM. Long-term child follow-up of the pravastatin for prevention of preeclampsia pilot trials. Am. J. Obstet. Gynecol. 2022; 226 (1): S74-S75.
https://doi.org/10.1016/j.ajog.2021.11.142
McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: A cohort studyusing thegeneral practice research database to investigate pregnancy loss. Pharmacoepidemiol. Drug Saf. 2017; 26 (7): 843-852.
https://doi.org/10.1002/pds.4176
Lefkou E, Varoudi K, Pombo J, et al. Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in mice and women through a nitric oxide-dependent mechanism. Biochem. Pharmacol. 2020; 182: 114217
https://doi.org/10.1016/j.bcp.2020.114217
Lefkou E, Mamopoulos A, Dagklis T, et al. Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy. J. Clin. Invest. 2016; 126 (8), 2933-2940.
https://doi.org/10.1172/JCI86957
Akbar MIA, Aziz MA, Riu DS, et al. INOVASIA study: A multicenter randomized clinical trial of pravastatin to prevent preeclampsia in high risk patients. Am J Perinatol. 2022.
https://doi.org/10.1055/a-1798-1925
Higgins J, Thomas J, Chandler J, et al. Cochrane handbook for systematic reviews of interventions. London: Cochrane. 2022.
Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: Cohort study. BMJ. 2015; 350, h1035.
https://doi.org/10.1136/bmj.h1035
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ. 2020; 372: n71-1.
https://doi.org/10.1136/bmj.n71
Russo MW. How to Review a Meta-analysis. Gastroenterol Hepatol (N Y). 2007 Aug; 3(8): 637-42.
Harrer M, Cuijpers P, Furukawa TA, et al. Doing meta-analysis with R: ahands-on guide. 1st ed. Boca Raton, FL: Chapman & Hall. 2021.
https://doi.org/10.1201/9781003107347
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002. 21:1539-58.
https://doi.org/10.1002/sim.1186
Core R, Team R. a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing. 2022
Schwarzer G. Meta: general package for meta-analysis. Cham: Springer. 2022.
https://doi.org/10.1002/9781119099369.ch26
Akbar M, Yosediputra A, Pratama R, et al. INOVASIA study: a randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1/PlGF levels. Am J Perinatol. 2021.
https://doi.org/10.1055/a-1673-5603
Deviana SR, Sunarno I, Lukas E, et al. The effect of pravastatin on endothelin-1 levels and pregnancy outcomes in women who have a high risk for preeclampsia: A randomized control trial. Enferm. Clin. 2020; 30, 499-505.
https://doi.org/10.1016/j.enfcli.2019.07.147
Costantine MM, West H, Wisner KL, et al. A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia. Am. J. Obstet. Gynecol. 2021;225(6):666.e1-666.e15.
https://doi.org/10.1016/j.ajog.2021.05.018
Ahmed A, Williams DJ, Cheed V, et al. Pravastatin for early-onset pre-eclampsia: A randomised, blinded, placebo-controlled trial. BJOG. 2020; 127: 478 488.
https://doi.org/10.1111/1471-0528.16013
Costantine MM, Cleary K, Hebert MF, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: A pilot randomized controlled trial. Am.J.Obstet.Gynecol. 2016; 214 (6), e1-e720. doi:10.1016/j.ajog.2015. 12.038
https://doi.org/10.1016/j.ajog.2015.12.038
Hassanain MS, Abdel-Aziz BR, Elsayed MA. Effect of pravastatin on the incidence of preeclampsia. Egypt J Hosp Med. 2018; 73: 7104-7111.
https://doi.org/10.21608/ejhm.2018.17508
Dobert M, Varouxaki AN, Mu AC, et al. Pravastatin versus placebo in pregnancies at high risk of term preeclampsia. Circulation. 2021;144: 670-679.
https://doi.org/10.1161/CIRCULATIONAHA.121.053963
Higgins JPT, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343 (7829): d5928-d5929.
https://doi.org/10.1136/bmj.d5928
Wójtowicz A, Zembala-szczerba M, Babczyk D, et al. Early and late onset preeclampsia: A comprehensive cohort study of Laboratory and Clinical Findings according to the New ISHHP Criteria. Int J Hypertens. 2019: 4108271.
https://doi.org/10.1155/2019/4108271
Ananth C, Keyes K, Wapner R. Pre-eclampsia rates in the United States, 1980-2010:age-period-cohort analysis. BMJ. 2013; 347:f6564.
https://doi.org/10.1136/bmj.f6564
Mendoza M, Ferrer-Oliveras R, Bonacina E, et al. Evaluating the effect of pravastatin in early-onset fetal growth restriction: A nonrandomized and historically controlled pilot study. Am. J. Perinatol. 2020; 1 (212), 1472-1479
https://doi.org/10.1055/s-0040-1713651
Pollack PS, Shields KE, Burnett DM, et al. Pregnancy outcomes after maternal exposure to simvastatin andlovastatin. Birth Defects Res. A Clin. Mol. Teratol. 2005; 73 (11): 888-896.
https://doi.org/10.1002/bdra.20181
Brown MA, Magee LA, Kenny LC, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2021; 72:24-43.
https://doi.org/10.1161/HYPERTENSIONAHA.117.10803
Brown M, Magee L, Kenny L, et al. International society for the study of hypertension in pregnancy (ISSHP). Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension. 2018; 72:24-43.
https://doi.org/10.1161/HYPERTENSIONAHA.117.10803
Steegers E, von Dadelszen P, Duvekot J, et al. Lancet. 2010; 376:631-44
https://doi.org/10.1016/S0140-6736(10)60279-6
Ishimwe J. Maternal microbiome in preeclampsia pathophysiology and implicationson offspring health. Physiol Rep. 2021; 9:e14875.
https://doi.org/10.14814/phy2.14875
Ma'ayeh M, Rood K, Kniss D, et al. Novel interventions for the prevention of preeclampsia. Curr Hypertens Rep. 2020; 22:17.
https://doi.org/10.1007/s11906-020-1026-8
Gajzlerska-Majewska W, Bomba-Opon D, Wielgos M. Is pravastatin a milestone inthe prevention and treatment of preeclampsia? J Perinat Med. 2018; 46:825-31.
https://doi.org/10.1515/jpm-2017-0109
Dymara-Konopka W, Laskowska M, Bła˙zewicz A. Angiogenic imbalance as acontributor of preeclampsia. Curr Pharm Biotechnol. 2018; 19:797-815.
https://doi.org/10.2174/1389201019666180925115559
Knapp G, Hartung J. Improved tests for a random effects meta-regression with asingle covariate. Stat Med. 2003; 22:2693-710.
https://doi.org/10.1002/sim.1482
Sweeting M, Sutton A, Lambert P. What to add to nothing? use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004; 23:1351-75.
https://doi.org/10.1002/sim.1761
IntHout J, Ioannidis J, Borm G. The hartung-knapp-sidik-jonkman method for random effects meta-analysis is straight forward and considerably out performs the standard dersimonian-laird method. BMC Med Res Methodol. 2014; 14:25.
https://doi.org/10.1186/1471-2288-14-25
Xu T, Zhou F, Deng C, et al. Low-dose aspirin for preventingpreeclampsia and its complications: a meta-analysis. J Clin Hypertens. 2015; 17:567-73.
https://doi.org/10.1111/jch.12541
Mészáros B, Veres DS, Nagyistók L, et al. Pravastatin in preeclampsia: A meta-analysis and systematic review. Front Med (Lausanne). 2023 Jan 13;9:1076372.
https://doi.org/10.3389/fmed.2022.1076372
Hirsch A, Rotem R, Ternovsky N, et al. Pravastatin and placental insufficiency associated disorders: A systematic review and meta-analysis. Front Pharmacol. 2022; Nov 9;13:1021548.
https://doi.org/10.3389/fphar.2022.1021548
Meijerink L, Wever KE, Terstappen F, et al. Statins in pre-eclampsia or fetal growth restriction: A systematic review and meta-analysis on maternal blood pressure and fetal growth across species. BJOG. 2023; May;130(6):577-585.
https://doi.org/10.1111/1471-0528.17393
Zarek J, Koren G. The fetal safety of statins: a systematic review and meta-analysis. J Obstet Gynaecol Can. 2014 Jun; 36(6):506-509.
https://doi.org/10.1016/S1701-2163(15)30565-X
Burton G, Redman C, Roberts J, Moffett A. Pre-eclampsia: pathophysiology andclinical implications. BMJ. 2019; 366:l2381
https://doi.org/10.1136/bmj.l2381
Mikhailidis D, Athyros V. Dyslipidaemia in 2013: new statin guidelines andpromising novel therapeutics. Nat Rev Cardiol. 2014; 11:72-4.
https://doi.org/10.1038/nrcardio.2013.209
Smith D, Costantine M. The role of statins in the prevention of preeclampsia. Am JObstet Gynecol. 2022; 226:S1171-81.
https://doi.org/10.1016/j.ajog.2020.08.040
Smith DD, Costantine MM. The role of statins in the prevention of preeclampsia. Am J Obstet Gynecol. 2022; 226: S1171 S1181
https://doi.org/10.1016/j.ajog.2020.08.040
Staff AC, Redman CWG. Comprehensive Gynecology and Obstetrics: The Differences Between Early- and Late-Onset Pre-eclampsia. Singapore: Springer Nature. pp. 2018; 157-172.
Downloads
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright Notice
All articles submitted by the author and published in the Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan, are fully copyrighted by the publication of Jurnal Profesi Medika : Jurnal Kedokteran dan Kesehatan under the Creative Commons Attribution-NonCommercial 4.0 International License by technically filling out the copyright transfer agreement and sending it to the publisher
Note :
The author can include in separate contractual arrangements for the non-exclusive distribution of rich versions of journal publications (for example: posting them to an institutional repository or publishing them in a book), with the acknowledgment of their initial publication in this journal.
Authors are permitted and encouraged to post their work online (for example: in an institutional repository or on their website) before and during the submission process because it can lead to productive exchanges, as well as earlier and more powerful citations of published works. (See Open Access Effects).
